News and Trends 25 Oct 2018 Invisible Eye Glucose Monitor Accurately Measures Sugar Levels In a small trial in the Netherlands, Dutch firm NovioSense has shown that its device for measuring blood sugar levels through tear fluid is comparable to current continuous glucose sensors. Currently, the standard method for people with diabetes to measure their blood sugar requires finger pricking multiple times per day, which can be painful and […] October 25, 2018 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 3 Oct 2018 Algorithm Proves Better Than Humans at Controlling Blood Sugar in Type 1 Diabetes A clinical trial has shown that letting an algorithm decide the amount of insulin a person with type 1 diabetes needs can help keep blood sugar levels under control. The algorithm, being developed at the University of Cambridge, is able to predict how much insulin is needed at each point in time based on the […] October 3, 2018 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 10 Sep 2018 Cambridge Biotech Targets Artificial Pancreas Market With Fast Insulin and Stable Glucagon UK biotech Arecor has raised €6.7M to help fund development of its extra-fast insulin and stable glucagon products for people with insulin-dependent diabetes. The speed of action of insulin has been a limiting factor for development of the artificial pancreas — a combined insulin pump and glucose monitor that would allow real-time control of blood […] September 10, 2018 - 2 minutesmins - By Helen Albert Share WhatsApp Twitter Linkedin Email
News and Trends 10 Sep 2018 Update: Non-Invasive Glucose Monitoring Device Moves Forward With Series B Funding Update (10/09/2018): RSP Systems has raised an additional €3.85M that raises the total amount of its Series B fundraising to €10.35M. The funds will be used to run clinical trials with the company’s device, which measures blood sugar without the need for finger-pricking. Published on 11/06/2018 RSP Systems has raised €6.5M in the first closing […] September 10, 2018 - 2 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
News and Trends 6 Sep 2018 Insulin Combo Reduces After-Meal Sugar Spikes in Type 1 Diabetics In the midst of a legal litigation with Eli Lilly, Adocia has released Phase 1 data showing its insulin combo can outperform Lilly’s fast-acting insulin in keeping sugar levels low after a meal. The trial, which recruited 24 type 1 diabetics, studied the effect of Adocia’s BioChaperone pramlintide insulin on glucose levels right after […] September 6, 2018 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 17 Aug 2018 Novo Nordisk Buys British ‘Smart’ Insulin Diabetes Biotech in deal worth €702M Novo Nordisk acquired the UK biotech Ziylo, which develops glucose-responsive insulin treatments for diabetes that act in response to changes in blood sugar levels. The Danish big-pharma, which is already a big player in the diabetes space, acquired the full rights to Ziylo’s technology in a deal worth up to €702M ($800M). Novo will use the […] August 17, 2018 - 2 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
News and Trends 16 May 2018 Swedish Biotech Partners With Novo Nordisk to Advance Stem Cell Therapies for Diabetes BioLamina has partnered with Novo Nordisk to develop stem cell therapies for diabetes and other conditions using a unique cell culture matrix technology. BioLamina, based in Stockholm, is collaborating with the world-leader in diabetes treatment Novo Nordisk to develop stem cell therapies that use BioLamina’s protein cell culture matrices. BioLamina’s technology could enhance Novo Nordisk’s […] May 16, 2018 - 2 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
News and Trends 16 Apr 2018 French Double-Hormone Diabetes Treatment to be Tested in Humans for the First Time Adocia, a French biotech, will initiate a Phase I clinical study to test a diabetes treatment that maximizes the effect of two blood sugar-lowering hormones. Adocia will start a Phase I clinical trial to test the safety and tolerability of its BioChaperone Pramlintide Insulin treatment to control blood sugar levels after a meal in type 1 […] April 16, 2018 - 2 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
More News! 12 Apr 2018 Graphene Skin Patch Measures Blood Sugar Without a Needle Researchers in the UK have developed a skin patch that measures blood sugar levels without the prick of a needle by pulling fluid out from between hair follicles. The technology could be used for both type 1 and type 2 diabetes patients. Diabetes is a major global health problem, with the World Health Organization stating 422 […] April 12, 2018 - 2 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
News and Trends 3 Apr 2018 Cheese-Producing Bacteria Could Help Reverse Type 1 Diabetes ActoBio Therapeutics has received permission from the FDA to start a clinical trial for a type 1 diabetes treatment that uses a bacterial strain also used in cheese production. After being cleared by the FDA, ActoBio, based in Belgium, plans to begin a PhaseIb/IIa study for its drug, AG019, to treat early-onset type 1 diabetes. What makes […] April 3, 2018 - 2 minutesmins - By Editorial Team Share WhatsApp Twitter Linkedin Email
News and Trends 15 Mar 2018 This Swedish Discovery Could Change the Way We Treat Diabetes Swedish researchers have found that insulin-producing cells alone are not enough to fine-tune blood sugar levels. This could change the way diabetes treatments are designed. While it is known that certain clusters of cells in the pancreas called pancreatic islets influence the set point for blood sugar, the exact mechanisms are still unknown. The control of […] March 15, 2018 - 3 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
News and Trends 13 Mar 2018 French Biotech Takes its Oral Diabetes Drug to Phase III Update (13/03/2018): Poxel has started two more Phase III trials in Japan testing its drug for type 2 diabetes, imeglimin. This oral drug has shown potential to lower glucose levels thanks to a mechanism of action that targets the pancreas, the liver and muscles simultaneously. The new trials will confirm whether these effects are maintained in a larger […] March 13, 2018 - 3 minutesmins - By Melanie De Almeida Share WhatsApp Twitter Linkedin Email